Korean CHA Bio, U.S. ACT Ink $1.9 Billion Licensing Deal
This article was originally published in PharmAsia News
Executive Summary
South Korean biotech CHA Bio & Diostech has licensed a retinal pigment epithelium technology from U.S.-based Advanced Cell Technology. The agreement restricts CHA Bio's development and marketing of an end product to treat eye diseases to Korea only. The contract calls for milestone payments to ACT for as much as $1.9 billion, with ACT to have U.S. development rights. ACT expects to begin clinical trials later this year. The two companies have been engaged in other joint ventures for hemangioblast technology. (Click here for more